Saturday, November 2, 2024

Canada’s Politics and Government News Source Since 1989

Saturday, November 2, 2024 | Latest Paper

TRENDING:

Doug Earle

Will the government stop the changes to PMPRB?

If you’re a Canadian who lives with a rare disease, needs precision cancer medicine, or who has come out of the COVID pandemic convinced

Opinion | BY DOUG EARLE | December 1, 2021

Many patient groups are urging the federal government not to bring in changes to the countries that Canada uses to compare drug prices, as recommended by the Patented Medicine Prices Review Board, which operates at arm’s-length from the Minister of Health Jean-Yves Duclos, pictured on Oct. 26. Many stakeholders worry that the regulations give too much power to an agency that operates at arms length from the government and is reluctant to hear (and sometimes openly dismissive of) input from key stakeholders like the patients who are most affected by drug prices, writes Doug Earle. The Hill Times photograph by Andrew Meade

Will the government stop the changes to PMPRB?

Opinion | BY DOUG EARLE | December 1, 2021

If you’re a Canadian who lives with a rare disease, needs precision cancer medicine, or who has come out of the COVID pandemic convinced

Will the government stop the changes to PMPRB?

Opinion | BY DOUG EARLE | December 1, 2021

If you’re a Canadian who lives with a rare disease, needs precision cancer medicine, or who has come out of the COVID pandemic convinced

Many patient groups are urging the federal government not to bring in changes to the countries that Canada uses to compare drug prices, as recommended by the Patented Medicine Prices Review Board, which operates at arm’s-length from the Minister of Health Jean-Yves Duclos, pictured on Oct. 26. Many stakeholders worry that the regulations give too much power to an agency that operates at arms length from the government and is reluctant to hear (and sometimes openly dismissive of) input from key stakeholders like the patients who are most affected by drug prices, writes Doug Earle. The Hill Times photograph by Andrew Meade

Will the government stop the changes to PMPRB?

If you’re a Canadian who lives with a rare disease, needs precision cancer medicine, or who has come out of the COVID pandemic convinced

Opinion | BY DOUG EARLE | December 1, 2021

Many patient groups are urging the federal government not to bring in changes to the countries that Canada uses to compare drug prices, as recommended by the Patented Medicine Prices Review Board, which operates at arm’s-length from the Minister of Health Jean-Yves Duclos, pictured on Oct. 26. Many stakeholders worry that the regulations give too much power to an agency that operates at arms length from the government and is reluctant to hear (and sometimes openly dismissive of) input from key stakeholders like the patients who are most affected by drug prices, writes Doug Earle. The Hill Times photograph by Andrew Meade

Will the government stop the changes to PMPRB?

Opinion | BY DOUG EARLE | December 1, 2021

If you’re a Canadian who lives with a rare disease, needs precision cancer medicine, or who has come out of the COVID pandemic convinced

Will the government stop the changes to PMPRB?

Opinion | BY DOUG EARLE | December 1, 2021

If you’re a Canadian who lives with a rare disease, needs precision cancer medicine, or who has come out of the COVID pandemic convinced

Many patient groups are urging the federal government not to bring in changes to the countries that Canada uses to compare drug prices, as recommended by the Patented Medicine Prices Review Board, which operates at arm’s-length from the Minister of Health Jean-Yves Duclos, pictured on Oct. 26. Many stakeholders worry that the regulations give too much power to an agency that operates at arms length from the government and is reluctant to hear (and sometimes openly dismissive of) input from key stakeholders like the patients who are most affected by drug prices, writes Doug Earle. The Hill Times photograph by Andrew Meade